⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CELC News
Celcuity Inc. Common Stock
Form 8-K
sec.gov
CELC
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
globenewswire.com
CELC
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
globenewswire.com
CELC
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2-
globenewswire.com
CELC
Form 8-K
sec.gov
CELC
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
globenewswire.com
CELC
Celcuity To Participate in Upcoming Investor Conferences
globenewswire.com
CELC
Form 8-K/A
sec.gov
CELC
Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer
prnewswire.com
CELC
NTRA
Form 8-K
sec.gov
CELC